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Abstract  
Background: The coagulation system is closely linked with vascular inflammation, although the 
underlying mechanisms are still obscure. Recent studies show that protease-activated receptor 
(PAR)-2, a major receptor of activated factor X (FXa), are expressed in both vascular cells and 
leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. 
Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis. 
Methods: We generated apolipoprotein E-deficient (ApoE-/-) mice lacking systemic PAR-2 
expression (PAR-2-/-ApoE-/-). ApoE-/- mice which lack or express PAR-2 only in bone-marrow (BM) 
cells were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 
weeks on a western-type diet (WTD) by histological analyses, quantitative RT-PCR, and western 
blotting. In vitro experiments using BM-derived macrophages were performed to confirm pro-
inflammatory roles of PAR-2. The association between plasma FXa level and the severity of 
coronary atherosclerosis was also examined in humans who underwent coronary intervention. 
Results: PAR-2-/-ApoE-/- mice showed reduced atherosclerotic lesions in the aortic arch (P<0.05) 
along with features of stabilized atherosclerotic plaques such as less lipid deposition (P<0.05), 
collagen loss (P<0.01), macrophage accumulation (P<0.05), and inflammatory molecule 
expression (P<0.05) compared with ApoE-/- mice. Systemic PAR2 deletion in ApoE-/- mice 
significantly decreased the expression of inflammatory molecules in the aorta. The results of BM 
transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to 
atherogenesis in ApoE-/- mice. PAR-2 deletion did not alter metabolic parameters. In vitro 
experiments demonstrated that FXa or a specific peptide agonist of PAR-2 significantly increased 
expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type 
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mice compared with those from PAR-2-deficient mice. Activation of NF-κB signaling was involved 
in PAR-2-associated vascular inflammation and macrophage activation. In humans who underwent 
coronary intervention, plasma FXa level independently correlated with the severity of coronary 
atherosclerosis as determined by Gensini score (P<0.05) and plaque volume (P<0.01). 
Conclusions: PAR-2 signaling activates macrophages and promotes vascular inflammation, 
increasing atherosclerosis in ApoE-/- mice. This signaling pathway may also participate in 
atherogenesis in humans. 
 
Keywords: macrophage, atherosclerosis, inﬂammation, protease-activated receptor-2 
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Clinical Perspective 
(1) What is new? 
 Systemic deletion or hematopoietic deletion of protease-activated receptor-2 (PAR-2) 
attenuates vascular inflammation and atherogenesis in atherosclerotic mouse model. 
 The activation of PAR-2 promotes pro-inflammatory activation of macrophages as 
determined by inflammatory molecule expression and foam cell formation. 
 In humans, plasma FXa level positively correlates with the severity of coronary artery 
disease such as Gensini score and plaque volume determined by intravascular ultrasound 
analysis. 
 In addition to classical coronary risk factors, plasma FXa level predicts the severity of 
coronary artery disease. 
(2) What are the clinical implications? 
 The PAR-2 signaling plays an important role in the development of vascular inflammation 
and atherosclerosis.  
 The PAR-2 signaling pathway may provide a novel mechanism of atherogenesis and serve 
as a potential therapeutic target for atherosclerosis. 
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Introduction 
It is a widely accepted view that atherosclerosis is a chronic inflammatory disease 1, 2. Many cellular 
and molecular pathways cause vascular inflammation 3, 4. Previous reports have suggested a link 
between the blood coagulation system and inflammatory diseases 5, 6. Several coagulation 
proteases and protease-activated receptor (PAR) pathways serve as underlying mechanisms 7-11. 
PARs are a family of G protein-coupled, seven transmembrane domain receptors that are activated 
by proteolytic cleavage of the receptor N-terminus by several proteases, generating a novel 
tethered ligand, which subsequently activates the receptor via intramolecular binding. Among the 
four subtypes of the PAR family, recent studies demonstrated that PAR-2, one of the major 
receptors of activated factor X (FXa), is expressed in vascular cells (i.e., endothelial cells and 
smooth muscle cells) and leukocytes, but not in platelets 7, 10, 11, and contributes to the development 
of inflammatory diseases, such as insulin resistance 12 and neointima formation after vascular injury 
13. However, the role of PAR-2 signaling in the development of atherosclerosis is not fully 
understood. Several studies have reported that PAR-2 in endothelial cells plays an important role 
in the pathophysiology of inflammatory diseases 14-16; however, little is known about the role of 
PAR-2 in macrophage activation, which is a key player in atherogenesis. 
Recently, we reported that a direct FXa inhibitor, rivaroxaban, attenuates atherosclerotic 
plaque progression and destabilization in apolipoprotein E-deficient (ApoE-/-) mice 17. Consistent 
with the results of our animal study, recent clinical trials demonstrated that patients with acute 
coronary syndrome treated with rivaroxaban experienced fewer cardiovascular events compared 
with the control 18-20. Furthermore, the result of the Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (COMPASS) trial demonstrated that the addition of low-dose 
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rivaroxaban to aspirin reduced major adverse cardiovascular events in patients with coronary or 
peripheral artery disease compared with traditional aspirin alone group 21. The anti-coagulation 
effects of FXa inhibitors might play a role in these results, although these studies also suggest that 
the inhibition of FXa-PAR-2 signaling by a FXa inhibitor might have anti-atherosclerotic effects 
through attenuation of vascular inflammation. 
In this study, to address the hypothesis that FXa-PAR-2 signaling, especially in 
macrophages, promotes vascular inflammation and atherosclerosis, we performed in vivo studies 
using ApoE-/- mice that genetically lack PAR-2 (PAR-2-/-ApoE-/- mice) and bone marrow (BM) 
chimeric ApoE-/- mice which lack or express PAR-2 only in hematopoietic cells. In vitro experiments 
using macrophages were also performed to investigate the role of PAR-2 in pro-inflammatory 
activation of this cell-type. Furthermore, we examined the relationship between plasma FXa level 
and the severity of coronary atherosclerosis in human to obtain clinically translatable evidence that 
FXa-PAR-2 signaling is involved in the development of atherosclerosis. The results of our study 
suggest a novel mechanism of atherogenesis that could serve as a potential therapeutic target. 
 
 
Methods 
All data and supporting materials have been provided with the published article. 
 
Animals 
Male ApoE-/- mice and PAR-2-deficient (PAR-2-/-) mice (C57BL/6J background), originally 
purchased from Jackson Laboratory, were used in this study. We generated PAR-2-/-ApoE-/- mice 
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by cross-breeding PAR-2-/- mice and ApoE-/- mice. Sex-age-matched ApoE-/- mice served as the 
control. We administered a western-type diet (WTD) for 20 weeks from 8 weeks of age. Some of 
8-week-old male PAR-2-/-ApoE-/- mice received a WTD supplemented with rivaroxaban (5 mg/kg 
body weight/day) for 20 weeks 17. Sex-age-matched non-treated PAR-2-/-ApoE-/- mice were served 
as the control. Rivaroxaban was supplied by Bayer Health Care. The mice were housed in a room 
in which lighting was controlled (12 h on/12 h off), and room temperature was kept at 25 °C. All 
experimental procedures conformed to the guidelines for animal experimentation of Tokushima 
University. The protocol was reviewed and approved by our institutional ethics committee. 
 
Bone marrow transplantation 
To investigate the role of PAR-2 in hematopoietic cells, we performed bone marrow transplantation 
(BMT) as described previously 22. For generating ApoE-/- mice which lack PAR-2 in hematopoietic 
cells, BM of ApoE-/- mice was reconstituted with that of PAR-2-/-ApoE-/- mice. For generating ApoE-
/- mice which express PAR-2 only in hematopoietic cells, BM of PAR-2-/-ApoE-/- mice was 
reconstituted with that of ApoE-/- mice. ApoE-/- mice which BM was replaced with that of ApoE-/- 
mice and PAR-2-/-ApoE-/- mice which BM was replaced with that of PAR-2-/-ApoE-/- mice were used 
for the control respectively. BM cells were harvested from the femurs and tibias of female donor 
mice. Eight-week-old male recipient mice were lethally X-irradiated with a total dose of 9.0 Gy. One 
day later, recipient mice received unfractionated BM cells by injection into the tail vein. At 8 weeks 
after BMT, all animals were started on a WTD. The replacement rate of BM cells was determined 
by fluorescence in-situ hybridization (FISH) of the X and Y chromosomes in male recipient mice 
repopulated with female BM 23. Interphase nucleic slides were prepared from spleen using an air-
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drying method. FISH analysis was performed using mouse X and Y chromosome probes 
(Chromosome Science Labo) following the manufacturer’s protocol, and the signals were observed 
under an all-in-one fluorescence microscope BZ-9000 (KEYENCE Japan). We used only BM 
chimeric mice in which more than 90% of BM had been replaced by donor BM. 
 
Blood pressure and plasma lipid level measurement 
The blood pressure of each mouse was measured using a tail-cuff system (BP-98A, Softron) in 
conscious animals. The average value of three measurements was used for comparison. At the 
time of sacriﬁce, blood was collected from the heart into K2-EDTA-containing tubes. After 
centrifuged, plasma was stored at -80°C until required. Plasma lipid levels were measured using 
commercially available kits (Wako Diagnostics). 
 
Preparation of aortas and atherosclerotic lesion analysis 
Atherosclerotic lesion analysis was performed as described previously 17. Mice were sacriﬁced by 
administration of an overdose of pentobarbital, and perfused with 0.9% sodium chloride solution at 
a constant pressure via the left ventricle. Both the heart and whole aorta were immediately removed. 
The thoracic aorta was excised, opened longitudinally, and ﬁxed with 10% neutral buffered formalin. 
To quantify atherosclerotic lesions in the aortic arch, en face Sudan IV staining was performed. The 
percentage of the Sudan IV-positive area was measured. The abdominal aorta was removed and 
snap-frozen in liquid nitrogen for gene or protein expression analysis. 
 
Histology and immunohistochemical analyses 
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Histological and immunohistochemical staining were performed as described previously 17. Each 
heart was cut along a horizontal plane between the lower tips of the left and right atria. The upper 
portion was snap-frozen in OCT compound (TissueTeck). Then, the aortic root was sectioned 
serially (5 μm intervals) from the point where the aortic valves appeared to the ascending aorta, 
until the valve cusps were no longer visible. Lipid and collagen content within atherosclerotic 
plaques were determined by Oil red O staining and picrosirius red staining, respectively. 
Macrophage antigen-3 (Mac-3), monocyte chemotactic protein-1 (MCP-1) and matrix 
metallopeptidase (MMP)-9 expression were detected using anti-macrophage antigen-3 (BD 
Biosciences), anti-MCP-1 (Santa-Cruz) or anti-MMP-9 (R&D Systems Inc.) antibody followed by 
the avidin-biotin complex technique, and stained using a Vector Red substrate kit (Vector). Each 
section was counterstained with hematoxylin. 
 
Cell culture 
BM-derived macrophages were used in this study. BM cells were obtained from femurs and tibias 
of 8-week-old wild-type mice and PAR-2-/- mice. Cells were cultured in DMEM supplemented with 
10 ng/ml macrophage colony-stimulating factor (R&D Systems) for 7 days. To assess the role of 
PAR-2 in macrophage activation, BM-derived macrophages from wild-type mice and PAR-2-/- mice 
were treated with 50 nM activated factor X (FXa) (Haematologic Technologies, Inc.) or 10 nM PAR-
2 specific agonist peptide (AP-2; Sigma-Aldrich) for 24 h after 24-h serum starvation. In addition, 
to assess the role of FXa-PAR-2 signaling in foam cell formation, BM-derived macrophages from 
wild-type mice and PAR-2-/- mice were pre-treated with 50 nM FXa or 10 nM AP-2 for 24 h, and 
then cultured with 100 μg/mL oxidized LDL (oxLDL, Biomedical Technologies Inc.) for 48 h. 
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Intracellular lipids were stained by Oil red O staining after ﬁxation with 10% neutral buffered formalin. 
The ratio of Oil red O-positive area/cellular area (%) was calculated in 100 cells and averaged. All 
cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 
100 mg/ml streptomycin in a 5% CO2 humidiﬁed atmosphere. 
 
Reverse transcription, real-time polymerase chain reaction 
Total RNA was extracted from tissues and cells using an illustra RNAspin RNA Isolation Kit (GE 
Healthcare). Reverse transcription was performed using a QuantiTect Reverse Transcription kit 
(Qiagen) from 1 μg of the extracted total RNA. Quantitative real-time PCR (qPCR) was performed 
on an Mx3000P (Agilent Technologies) using gene-speciﬁc primers (Supplemental Table) and 
Power SYBR Green PCR Master Mix (Applied Biosystems). Data are expressed in arbitrary units 
that were normalized by β-actin. 
 
Western blot  
Protein were isolated from cells or tissue, and separated by SDS–polyacrylamide gel 
electrophoresis gels as we described previously23. The following antibodies were used: IκBα, and 
β-actin (Sigma). β-actin was used as an internal control. Antibody distribution was visualized with 
enhanced chemiluminescence-plus reagent (GE Healthcare) using a luminescent image analyzer 
(LAS-1000, Fuji Film). 
 
Clinical research 
We included patients with stable angina who had been receiving a statin for at least 6 months. All 
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patients underwent elective percutaneous coronary intervention (PCI) and intravascular ultrasound 
(IVUS) study of the vessel undergoing PCI. We excluded patients with acute coronary syndrome, 
renal insufficiency, history of PCI or coronary artery bypass surgery, and those with inadequate 
IVUS imaging. Blood samples were collected into Na-EDTA-containing tubes just before PCI. After 
blood samples were centrifuged, plasma was stored at -80°C until required. Plasma FXa level was 
measured using a commercially available kit (Human Coagulation factor Xa ELISA Kit; 
MBS721605, MyBioSource). All experimental procedures were approved by the Institutional 
Review Board of Tokushima University Hospital and all subjects were gave informed consent. 
We calculated Gensini scores 24 from initial angiograms as a global severity marker of 
coronary atherosclerosis. Our IVUS imaging protocol was described previously 25. In brief, we 
selected plaques of intermediate stenotic lesions (25% < percent diameter stenosis < 50% on 
quantitative coronary angiography) > 5 mm from the intervention site. We used imaging catheters 
(Atlantis; Boston Scientific/Cardiovascular System) and a console (Galaxy; Boston 
Scientific/Cardiovascular System). We captured 10 continuous slice images (total length 5 mm) at 
intervals of 0.5 mm using an auto-pullback system in each plaque. Cross-sectional lumen area, 
cross-sectional vessel area within the external elastic membrane, and plaque area were 
determined using software attached to the IVUS system. Plaque volume was calculated using 
integration. 
 
Statistical analysis 
Numerical values are expressed as mean ± SEM. Comparison of parameters between two groups 
was performed with unpaired Student's t-test when data followed a normal distribution or with 
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Mann-Whitney U test when data did not follow a normal distribution. Univariate analysis between 
the severity of coronary atherosclerosis (Gensini score and plaque volume) and plasma FXa level 
was performed by Spearman's rank correlation coefficient. Multiple regression analysis was 
performed for prediction of the Gensini score and coronary plaque volume using metabolic 
parameters and plasma FXa level. A value of P<0.05 was considered signiﬁcant. 
 
Results 
Genetic deletion of PAR-2 attenuated plaque progression and destabilization in ApoE-/- mice 
After 20 weeks of WTD feeding, en face Sudan IV staining of the aortic arch showed a significant 
reduction of atherosclerotic lesions in PAR-2-/-ApoE-/- mice compared with ApoE-/- mice (49.0±3.1 
vs. 38.9±3.7%, P<0.05) (Figure 1). Genetic deletion of PAR-2 demonstrated a signiﬁcant reduction 
of lipid deposition (6.98±0.21 vs. 6.23±0.21%, P<0.05) (Figure 2A) and an increase in collagen 
content (66.0±1.3 vs. 72.3±1.3%, P<0.01) (Figure 2B) in atherosclerotic plaques in ApoE-/- mice. 
Also, genetic deletion of PAR-2 in ApoE-/- mice signiﬁcantly reduced the accumulation of 
macrophages as determined by Mac-3 staining (5.35±0.58 vs. 3.02±0.58%, P<0.05) (Figure 2C) 
and the expression of MCP-1 (2.17±0.34 vs. 1.00±0.34%, P<0.05) (Figure 2D) and MMP-9 
(2.60±0.24 vs. 1.39±0.27%, P<0.05) (Figure 2E) in atherosclerotic plaques compared with control 
animals. There were no differences in body weight gain, blood pressure, plasma glucose level, and 
plasma lipid levels between ApoE-/- mice and PAR-2-/-ApoE-/- mice (Table 1). PAR-2 deletion did not 
affect plasma FXa level. These results indicated that genetic deletion of PAR-2 in ApoE-/- mice 
attenuates plaque progression and destabilization without alteration of metabolic parameters. 
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Genetic deletion of PAR-2 attenuated vascular inflammation in ApoE-/- mice 
We also compared the expression of inﬂammatory molecules in the atherosclerotic aorta using 
qPCR between ApoE-/- mice and PAR-2-/-ApoE-/- mice. Consistent with the results of 
immunohistochemical study, PAR-2-/-ApoE-/- mice demonstrated reduced expression of the 
macrophage marker F4/80 (P=0.05) compared with ApoE-/- mice. PAR-2-/-ApoE-/- mice also 
demonstrated a reduction of inﬂammatory molecules, such as MCP-1, macrophage inflammatory 
protein (MIP)-1α, interleukin (IL)-6 and MMP-9 (P<0.05, respectively) (Figure 3A). PAR-2 deletion 
attenuated the degradation of IκBα in the atherosclerotic aorta, suggesting inhibition of NF-κB 
signaling (Figure 3B). Genetic deletion of PAR-2 did not change RNA expression of PAR-1, PAR-
3, and PAR-4 (Figure 3C). These results indicated that genetic deletion of PAR-2 in ApoE-/- mice 
reduces vascular inflammation.  
 
FXa inhibition did not affect atherogenesis in PAR-2-/-ApoE-/- mice 
FXa activates both PAR-1 and PAR-2. Previous studies reported the expression of PAR-1 and 
PAR-2 in the vasculature and contribution to the development of vascular inflammation and 
atherogenesis 7, 10, 11. Therefore, to examine the role of FXa-PAR-2 signaling in atherogenesis, we 
administered a specific FXa inhibitor, rivaroxaban, to PAR-2-/-ApoE-/- mice for 20 weeks. 
Rivaroxaban attenuated atherogenesis in ApoE-/- mice as demonstrated in our previous study 17, 
although it did not inhibit the progression of atherosclerotic lesions in the aortic arch (35.1±2.3 vs. 
31.4±3.5%) and the expression of inflammatory molecules, except for IL-1β, in atherosclerotic aorta 
in PAR-2-/-ApoE-/- mice, suggesting the pivotal role of FXa-PAR-2 signaling in atherogenesis 
(Supplemental Figure 1). 
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PAR-2 in hematopoietic cells contributed to plaque progression and destabilization in 
ApoE-/- mice 
To further investigate the role of PAR-2 in hematopoietic cells in the development of atherosclerosis, 
we generated BM specific PAR-2 deleted or expressing ApoE-/- mice. The replacement rate of BM 
cells determined by fluorescence in-situ hybridization was more than 90% in all BM chimeric mice 
as shown in Supplemental Figure 2.  
 PAR-2 deletion in BM cells reduced the development of atherosclerotic lesions in the 
aortic arch (10.8±1.1 vs. 5.8±1.0%, P<0.01) (Figure 4A) and lipid deposition in atherosclerotic 
plaques in the aortic root (5.71±0.66 vs. 3.08±0.63%, P<0.01) (Figure 5A). In contrast, PAR-2 
deletion in BM cells signiﬁcantly increased collagen content in plaques (15.3±2.1 vs. 24.2±2.0%, 
P<0.01) (Figure 5B). Furthermore, the results of immunostaining of atherosclerotic lesions revealed 
that PAR-2 deletion in BM cells in ApoE-/- mice reduced the accumulation of macrophages as 
determined by Mac-3 staining (7.43±0.29 vs. 4.03±0.35%, P<0.01) (Figure 5C), and the expression 
of MMP-9 (6.13±0.18 vs. 4.25±0.48%, P<0.01) (Figure 5E) compared with control chimeric mice. 
The expression of MCP-1 was also lower in plaques in ApoE-/- mice lacking PAR-2 in BM cells 
compared with that in control mice (Figure 5D). On the other hand, BM specific PAR-2 expression 
promoted atherosclerotic lesion progression (Figure 4B). Lipid deposition and collagen loss in 
atherosclerotic lesions were greater in BM specific PAR-2 expressing mice compared to the control 
(Supplementary Figure 3). 
There were no differences in body weight gain, blood pressure, plasma glucose level, and 
plasma lipid levels despite the presence or absence of PAR-2 in BM (Table 2 and Supplementary 
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Table 2). These results indicated that PAR-2 in hematopoietic cells contributes to plaque 
progression and destabilization in ApoE-/- mice. Also, these results suggested that PAR-2 signaling 
in macrophages contributes, at least partially, to atherogenesis. 
 
PAR-2 in hematopoietic cells promoted vascular inflammation in ApoE-/- mice 
We also examined the role of PAR-2 in hematopoietic cells in the expression of inﬂammatory 
molecules in the atherosclerotic aorta using qPCR. PAR-2 deletion in hematopoietic cells reduced 
the expression of the macrophage marker F4/80 (P<0.05). PAR-2 deletion in BM cells also reduced 
the expression of inﬂammatory molecules, such as MCP-1 (P<0.05), MIP-1α (P<0.05), IL-1β 
(P<0.05), IL-6 (P<0.01), tumor necrosis factor (TNF)-α (P<0.05), and MMP-9 (P<0.01) (Figure 6A). 
On the other hand, PAR-2 expression in BM increased the expression of these inflammatory 
molecules (Figure 6B). These results indicated that PAR-2 in hematopoietic cells promotes the 
expression of inﬂammatory molecules in atherosclerotic aorta, leading to the development of 
vascular inflammation. 
 
PAR-2 signal promoted pro-inﬂammatory activation of macrophages 
To investigate the mechanism by which inhibition of PAR-2 signaling prevented the development 
and destabilization of atherosclerotic lesions without improvement of metabolic parameters, we 
performed in vitro experiments using BM-derived macrophages. We treated BM-derived 
macrophages with FXa, a major ligand of PAR-2, or a specific agonist peptide of PAR-2 (AP-2). 
The results of qPCR analysis demonstrated that the expression of inflammatory molecules (e.g., 
MCP-1, IL-6 and TNF-α) was significantly higher in BM-derived macrophages from wild-type mice 
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compared with those from PAR-2-/- mice after FXa or AP-2 treatment (Figure 7A). The result of 
western blotting demonstrated that the activation of PAR-2 signaling by FXa increased the 
degradation of IκBα, suggesting the activation of NF-κB in macrophages (Figure 7B). We further 
examined the role of PAR-2 signaling in lipid uptake by macrophages in vitro. The activation of 
PAR-2 signaling by FXa or AP-2 significantly increased uptake of oxidized low-density lipoprotein 
(oxLDL) by BM-derived macrophages from wild-type mice compared with those from PAR-2-/- mice 
(Figure 7C). These results suggested that PAR-2 signaling promotes pro-inﬂammatory activation 
of macrophages. 
 
Relationship between FXa-PAR-2 signaling and atherosclerosis in clinical samples 
To investigate the role of the FXa-PAR-2 signaling pathway in the development of atherosclerosis 
in humans, we investigated the link between plasma FXa level and the severity of coronary 
atherosclerosis. Blood samples, Gensini score and intravascular ultrasound (IVUS) data were 
obtained from 32 patients who underwent percutaneous coronary intervention. Patient 
characteristics at enrollment are shown in Table 3. Mean age of the participants was 69.6±1.1 
years; 63% were men. Plasma FXa level positively correlated with the Gensini score (Spearman 
ρ=0.36, P<0.05) (Figure 8A). Plasma FXa level tended to correlate positively with coronary plaque 
volume determined by intravascular ultrasound study (Spearman ρ=0.42, P=0.06) (Figure 8B). 
Multiple regression analysis revealed that plasma FXa level remained as an independent predictor 
of the Gensini score (corrected R2=0.29, P<0.05). Multiple regression analysis revealed that 
plasma FXa level, as well as male sex and HbA1c level, remained as independent predictors of 
coronary plaque volume (corrected R2=0.44, P<0.01) (Table 4). These results indicated that FXa 
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promotes vascular inflammation through PAR-2 and is associated with the severity of 
atherosclerosis in coronary arteries in humans. 
 
 
Discussion 
Accumulating evidence suggests that PAR-2 signaling promotes pro-inﬂammatory responses in 
many cell types 7, 10, 11, contributing to the pathogenesis of inﬂammatory diseases 12-16, although 
little is known about the role of PAR-2, especially in hematopoietic cells, in the development of 
vascular inflammation and atherosclerosis. In this study, in vivo experiments using PAR-2 deficient 
ApoE-/- mice and BM-specific PAR-2 expression or deletion animals demonstrated that PAR-2 
deletion attenuated vascular inflammation and reduced the development and destabilization of 
atherosclerotic lesions without the alteration of metabolic parameters including blood lipid levels. 
The results of in vitro experiments using peritoneal macrophages demonstrated that PAR-2 
signaling participates in pro-inflammatory activation of macrophages through NF-κB pathway. Our 
ﬁndings suggest that the PAR-2 signaling promotes vascular inflammation and atherogenesis, and 
that pro-inflammatory activation of macrophages through the PAR-2 signaling plays a pivotal role 
as an underlying mechanism. 
Previous reports demonstrated that several proteases including trypsin, tryptase and FXa, 
but not thrombin, activate PAR-2. Different from other members of the PAR family, platelets do not 
express PAR-2, whereas vascular cells, such as endothelial cells and smooth muscle cells, and 
leukocytes express PAR-2 11. Because of its unique expression pattern, previous studies 
investigated the role of PAR-2 in vascular functions. In fact, the contribution of PAR-2 to vasodilation 
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26, 27 and inflammatory responses 15, 16 has been reported. However, the role of PAR-2 signaling 
in macrophage activation is not fully investigated. Therefore, in this study, we generated BM-
chimeric mice which express or lack PAR-2 in BM. PAR-2 deletion in hematopoietic cells attenuated 
vascular inflammation and atherogenesis. On the contrary, PAR-2 expression only in hematopoietic 
cells promoted vascular inflammation and atherogenesis. Furthermore, our in vitro experiments 
demonstrated that treatment of macrophages with FXa, the major endogenous ligand of PAR-2, or 
AP-2, a specific agonist for PAR-2, increases inflammatory gene expression and lipid uptake, both 
of which are critical for atherosclerotic lesion progression and destabilization. These results 
suggested that PAR-2 plays a pivotal role in pro-inflammatory activation of macrophages, 
contributing to the development of vascular inflammation and atherogenesis. 
Several previous studies have already reported a role of PAR-2 in non-hematopoietic cells 
in the development of vascular inﬂammation in different models 28-31. Therefore, it is plausible that 
PAR-2 in non-hematopoietic cells such as endothelial cells may participate in atherogenesis. In 
fact, in our BMT experiments, expression of PAR-2 in the vasculature enhanced lesion 
development despite of the presence or absence of PAR-2 in hematopoietic cells. These results 
indicated pivotal roles of PAR-2 of both hematopoietic cells, especially macrophages, and non-
hematopoietic cells in atherogenesis, and suggested PAR-2 can be a potential therapeutic target 
against atherosclerosis.  
Since clinical approval as an anti-coagulant, a direct oral FXa inhibitor, rivaroxaban, 
attracts much attention because of its beneficial effects on cardiovascular events proved by several 
clinical trials 18-21. In our clinical study, plasma FXa level predicts the severity of coronary 
atherosclerosis such as Gensini score and coronary plaque volume. PAR-2 is activated by FXa 
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and upregulates inflammation through NF-κB pathway32-34. Therefore, the results of in vivo animal 
studies and in vitro studies of the present study may provide one of the possible mechanisms for 
recent clinical studies. Interestingly, recent studies have demonstrated that several coagulation 
factors such as tissue factor and factor X exist not only in the circulating blood but also in 
atherosclerotic plaques in human autopsy samples 35. In our present study, plasma FXa level 
between ApoE-/- mice and PAR-2-/-ApoE-/- mice did not differ, although, in our previous study, we 
reported higher expression of PAR-2 in atherosclerotic aorta of ApoE-/- mice compared with the 
aorta in wild-type mice 17. These results suggested that the role of FXa-PAR-2 signaling in vascular 
inflammation is enhanced in the atherosclerotic plaques. In addition, in this study, we could not 
observe the inhibitory effect of rivaroxaban on atherogenesis in PAR-2-/-ApoE-/- mice. This result 
also may give support to the role of FXa-PAR-2 signaling in the development of atherosclerosis at 
least partially. 
 This study has several limitations. First, to investigate the role of PAR-2 in macrophages, 
a key cell-type in atherogenesis, we performed BMT experiments. Previous studies demonstrated 
that other hematopoietic cells such as neutrophils express PAR-2. Although our in vitro studies 
using peritoneal macrophages showed that FXa-PAR-2 signaling participates in pro-inflammatory 
activation of macrophages, other hematopoietic cells activated by FXa-PAR-2 signaling might have 
contributed to the results of in vivo studies. Second, we only examined the role of FXa-PAR-2 
signaling in atherogenesis, however, FXa activates PAR-1 as well. Some of previous studies 
reported that contribution of PAR-1 to inflammation36, 37. Therefore, it might also participate in the 
development of atherosclerosis. Further studies are needed to clarify the role of FXa-PARs 
signaling in vascular inflammation and atherogenesis. Third our patient population in our clinical 
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study was small, and a large scale study is required to confirm our results. Lastly, in our clinical 
study, total cholesterol level did not predict the coronary atherosclerosis determined by IVUS. We 
speculate that because we included only patients receiving statins for at least 6 months, lipid levels 
were well controlled in this study population. 
Our present study demonstrated proof of the concept that PAR-2 signaling in 
macrophages plays a pivotal role in the development of atherosclerosis. Further studies are 
needed to elucidate the participation of FXa-PARs signaling in the development of vascular 
inﬂammation and atherosclerosis. In conclusion, PAR-2 deletion attenuates vascular inflammation 
and atherogenesis in ApoE-/- mice. PAR-2 in hematopoietic cells may contribute, at least in part, to 
the development of atherosclerosis. Combined with the results of our in vitro studies, these results 
indicated that PAR-2 signaling in macrophages plays a pivotal role in vascular inflammation. The 
PAR-2 signaling pathway may provide a novel mechanism of atherogenesis and serve as a 
potential therapeutic target for atherosclerosis. 
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Figure legends 
Figure 1. Effect of genetic deletion of RAR-2 on atherosclerotic lesion formation in ApoE-/- 
mice. 
En face Sudan IV staining of the aortic arch showed that PAR-2-/-ApoE-/- mice had reduced 
atherosclerotic lesions compared with ApoE-/- mice (n=9-13). Scale bar: 1 mm. *P<0.05. All values 
are mean ± SEM. 
 
Figure 2. Effect of genetic deletion of PAR-2 on characteristics of atherosclerotic plaques 
in ApoE-/- mice.  
(A) Oil red O staining of atherosclerotic plaques in the aortic root. Lipid deposition in plaques was 
decreased in PAR-2-/-ApoE-/- mice compared with that in ApoE-/- mice. Scale bar: 100 μm. (B) 
Picrosirius red staining observed under polarization microscopy. Collagen content in plaques was 
increased in PAR-2-/-ApoE-/- mice compared with that in ApoE-/- mice. Scale bar: 100 μm. (C-E) 
Immunostaining against Mac-3 (C), MCP-1 (D), and MMP-9 (E). PAR-2-/-ApoE-/- mice showed 
reduced accumulation of macrophages and less expression of MCP-1 and MMP-9 in 
atherosclerotic plaques compared with ApoE-/- mice. Scale bar: 50 μm. (n=10 in A and B, n = 5 in 
C through E, per group). Mac-3 indicates macrophage antigen-3; MCP-1, monocyte chemotactic 
protein-1; and MMP-9, matrix metallopeptidase-9. *P<0.05 and **P<0.01. All values are mean ± 
SEM. 
 
Figure 3. Effect of genetic deletion of PAR-2 on vascular inflammation.  
(A) qPCR analyses using abdominal aorta revealed that genetic deletion of PAR-2 decreased the 
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expression of F4/80, a macrophage marker. PAR-2 deletion also reduced the expression of 
inflammatory molecules, such as MCP-1, MIP-1α, IL-6 and MMP-9, in the atherosclerotic aorta 
(n=10-12). (B) The expression of IκBα was examined by western blotting. The degradation of IκBα 
was reduced in PAR-2 deficient animals, suggesting suppression of NF-κB activity (n=5). (C) 
Expression of PARs in the aorta. qPCR analyses using abdominal aorta revealed that genetic 
deletion of PAR-2 did not change the expression of PAR-1, PAR-3, and PAR-4. (n=10). ApoE‒/‒ 
indicates apolipoprotein E–deficient; IL, interleukin; MCP-1, monocyte chemotactic protein-1; MIP-
1 α, macrophage inflammatory protein α; MMP-9, matrix metallopeptidase-9; N.D., not detectable; 
and TNF- α, tumor necrosis factor-α. *P<0.05. All values are mean ± SEM. 
 
Figure 4. Role of PAR-2 in hematopoietic cells in atherosclerotic lesion formation. 
(A) En face Sudan IV staining of the aortic arch demonstrated that hematopoietic deletion of PAR-
2 in ApoE-/- mice reduced atherosclerotic lesion progression in the aortic arch compared with the 
control BM chimeric mice (n=9-10). (B) En face Sudan IV staining of the aortic arch demonstrated 
that hematopoietic restoration of PAR-2 in PAR-2-/-ApoE-/- mice accelerated atherosclerotic lesion 
progression in the aortic arch compared with the control BM chimeric mice  (n=5-7). Scale bar: 1 
mm. BM indicates bone marrow. *P<0.05 and **P<0.01. All values are mean ± SEM. 
 
Figure 5. Effect of hematopoietic deletion of PAR-2 on characteristics of atherosclerotic 
plaques in aortic root. 
(A) Oil red O staining of atherosclerotic plaques in the aortic root. PAR-2 deletion in BM cells 
reduced lipid deposition compared with the control group. Scale bar: 100 μm. (B) Picrosirius red 
CIRCULATIONAHA/2018/033544/R2 
Hara T, et al. Protease-Activated Receptor-2 in Atherogenesis 
31 
 
staining observed under polarization microscopy. Collagen content was increased in ApoE-/- mice 
lacking PAR-2 in BM cells compared with the control group. Scale bar: 100 μm. (C-E) 
Immunostaining against Mac-3 (C), MCP-1 (D), and MMP-9 (E). ApoE-/- mice lacking PAR-2 in BM 
cells demonstrated reduced accumulation of macrophages and less expression of MCP-1 and 
MMP-9 in atherosclerotic plaques compared with the control chimeric mice. Scale bar: 50 μm. 
(n=9-10 in A and B, n=5-10 in C through E, per group). BM indicates bone marrow; Mac-3, 
macrophage antigen-3; MCP-1, monocyte chemotactic protein-1; MIP-1 α, macrophage 
inflammatory protein α; and MMP-9, matrix metallopeptidase-9. **P<0.01. All values are mean ± 
SEM. 
 
Figure 6. Role of PAR-2 in hematopoietic cells in expression of inﬂammatory molecules in 
abdominal aorta. 
(A) qPCR analyses using abdominal aorta revealed that hematopoietic delete of PAR-2 in ApoE-/- 
mice decreased the expression of F4/80, a macrophage marker, and inflammatory molecules in 
the atherosclerotic aorta (n=7-8). (B) qPCR analyses using abdominal aorta revealed that 
hematopoietic restoration of PAR-2 in PAR-2-/-ApoE-/- mice increased inflammatory molecules in 
the atherosclerotic aorta (n=4-7). IL indicates interleukin; MCP-1, monocyte chemotactic protein-1; 
MIP-1 α, macrophage inflammatory protein α; MMP-9, matrix metallopeptidase-9; and TNF-α, 
tumor necrosis factor-α.*P<0.05 and **P<0.01. All values are mean ± SEM. 
 
Figure 7. Role of PAR-2 signaling in macrophage activation. 
(A) qPCR analysis demonstrated that FXa or AP-2 significantly increased the expression of 
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inflammatory molecules in BM-derived macrophages from wild-type mice compared with those 
from PAR-2-/- mice (n=4, per group). (B) The expression of IκBα in BM-derived macrophages was 
examined by western blotting. FXa enhanced the degradation of IκBα in wild-type macrophage but 
not in PAR-2-deficient macrophages (n=5-6). (C) Lipid uptake by BM-derived macrophages was 
examined by Oil red O staining. The activation of PAR-2 signaling by FXa or AP-2 significantly 
increased uptake of oxidized low-density lipoprotein (oxLDL) to BM-derived macrophages from 
wild-type mice compared with those from PAR-2-/- mice. The ratio of Oil red O positive area/cell 
area (%) was calculated in 100 cells under light microscopy and averaged. Scale bar: 10 μm. (n=4 
per group). AP-2 indicates specific agonist peptide of PAR-2; BM, bone marrow; FXa, activated 
factor X; IL, interleukin; MCP-1, monocyte chemotactic protein-1; MW, molecular weight; NT, 
nontreatment; TNF-α, tumor necrosis factor-α. and WT, wild-type. *P<0.05 and **P<0.01. All values 
are mean ± SEM. 
 
Figure 8. Relationship between plasma FXa level and severity of coronary atherosclerosis 
in humans. 
(A) Plasma FXa level in patients with stable angina showed a positive correlation with Gensini 
score. (B) Plasma FXa level in patients with stable angina tended to correlate with coronary plaque 
volume as determined by IVUS study. FXa indicates activated factor X; and IVUS, intravascular 
ultrasound. 
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Table 1. Effects of PAR-2 deletion on metabolic parameters. 
 ApoE-/- PAR-2-/-ApoE-/- P-value 
Body weight, g 38.8±1.8 43.0±1.5 0.07 
Heart rate /min 667±14 645±12 0.28 
Systolic BP, mmHg 110.5±3.7 115.7±3.0 0.29 
Diastolic BP, mmHg  80.1±3.8 84.2±3.1 0.41 
FXa, ng/ml 10.8±1.1 8.7±0.9 0.29 
Plasma glucose, mg/dl 133.7±6.2 131.5±5.0 0.78 
Triglyceride, mg/dl 117.0±31.2 114.5±26.4 0.95 
Total cholesterol, mg/dl 1084.3±179.0 1316.4±151.3 0.33 
HDL-C, mg/dl 20.5±5.0 26.0±4.3 0.41 
LDL-C, mg/dl 1040.3±173.0 1298.2±151.7 0.27 
All values are mean±SEM. ApoE‒/‒ indicates apolipoprotein E–deficient; BP, blood pressure, FXa, 
activated factor X; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; and PAR-2, protease-activated receptor. 
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Table 2. Effects of PAR-2 deletion in BM on metabolic parameters. 
Donor 
Recipient 
ApoE-/- 
ApoE-/- 
PAR-2-/-ApoE-/- 
ApoE-/- 
P-value 
Body weight, g 28.8±1.7 27.6±1.5 0.30 
Heart rate /min 667±14 667±14 0.49 
Systolic BP, mmHg 102.3±7.5 106.5±6.5 0.35 
Diastolic BP, mmHg 62.7±7.2 69.8±6.3 0.91 
Plasma glucose, mg/dl 131.3±6.3 122.8±5.5 0.25 
Triglyceride, mg/dl 186.3±23.9 223.8±29.7 0.34 
Total cholesterol, mg/dl 983.1±42.2 1147.0±79.5 0.09 
HDL-C, mg/dl 26.4±2.9 21.1±2.0 0.14 
LDL-C, mg/dl 919.4±44.3.4 1081.0±80.7 0.10 
All values are mean±SEM. ApoE‒/‒ indicates apolipoprotein E–deficient; BM, bone marrow; BP, 
blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; and PAR-2, protease-activated receptor.  
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Table 3. Patients' characteristics. 
 (N = 32) 
Age, yrs 69.6±1.1 
Male/female 20 (63) / 12 (37) 
Smoking 19 (59) 
Hypertension 30 (94) 
HbA1c, % 6.1±0.2 
Triglyceride, mg/dl 125±11 
Total cholesterol, mg/dl 176±6 
HDL-C, mg/dl 105±5         
LDL-C, mg/dl 52±2 
Data presented are mean±SEM or number (percentage). HDL-C indicates high-density 
lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.  
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Table 4. Multivariate analysis for prediction of the severity of coronary atherosclerosis. 
  Gensini score (log) Coronary plaque volume 
Corrected R2 
P-value 
 
 
0.29 
0.04 
 
 
0.44 
0.006 
  
 
Standard 
regression  
coefficient 
P-value  Standard 
regression 
coefficient 
P-value 
Plasma FXa level, ng/ml  0.520 0.003  0.568 0.0005 
Age, y  0.153 0.36  -0.104 0.48 
Male sex  0.097 0.62  0.399 0.03 
Smoking  0.265 0.16  -0.233 0.16 
Hypertension  -0.128 0.44  0.272 0.07 
HbA1c, %  0.003 0.99  0.511 0.002 
HDL-C, mg/dL  -0.287 0.21  -0.180 0.37 
Triglyceride, mg/dL  0.006 0.98  -0.182 0.35 
Total cholesterol, mg/dL  0.421 0.05  0.124 0.51 
FXa indicates activated factor X; and HDL-C, high-density lipoprotein cholesterol. 
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